Trajectories of responses to mepolizumab in severe asthma

In the past decade, the introduction of biologics designed to target key cytokines and receptors of the T2 inflammatory cascade has pushed the limits of what is achievable in terms of treatment outcomes. When used appropriately, they resolve symptoms and exacerbations, even in patients suffering from the most severe form of the disease [1]. As such, the paradigm of clinical remission on treatment – defined by the simultaneous achievement of key outcomes such as the absence of exacerbations, controlled symptoms, no oral corticosteroid (OCS) use, and stabilisation of lung function – has been accepted by many experts as an attainable target [2–4].